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Erythropoietin (EPO) is a glycoprotein hormone responsible for regulating erythropoiesis. Expression 
of EPO and EPO receptors (EPOr) has recently been demonstrated in some neoplastic cell lines and 
tumours, suggesting a potential new target for therapy. In this work, EPO was labeled with iodine-125 
using the lactoperoxidase method, known to prevent damage to protein during radioiodination, and 
labeling conditions were optimized. In vitro stability studies have shown that 125I-EPO is radiochemically 
stable for 20 days after radiolabeling. In vitro cell binding studies have demonstrated very low binding 
(<2%) of EPO to normal and neoplastic cell lines tested. As expected, the biodistribution in healthy 
mice exhibited comparatively high rates of fixation in the organs of the excretory system. Thyroid also 
proved to be a critical organ which may indicate in vivo dissociation of 125I-EPO. In mice with induced 
melanoma, only a residual fixation in the tumour was evident. Further studies are warranted on other 
tumoral cell lines to better understand the binding process and internalization into cells. Studies on EPO 
labeled with carbon-11 could be valuable, since there is a greater chance of preserving the biological 
activity of the protein using this method.
Uniterms: Erythropoietin (EPO). Glycoprotein hormone. 125I-erythropoietin/synthesis. 125I-erythropoietin/
biological evaluation. Erythropoiesis/regulation. Radiopharmaceuticals. Iodine-125/labelled. EPO 
expressive tumours.
A eritropoetina (EPO) é um hormônio glicoprotéico responsável pela regulação da eritropoese. 
Recentemente foi demonstrado que os receptores de EPO (EPOr) estão expressos em algumas linhas 
celulares neoplásicas, o que sugere a sua potencialidade como um novo alvo terapêutico. Neste trabalho 
a EPO foi radiomarcada com iodo-125 através do método da lactoperoxidase, menos agressivo para a 
viabilidade biológica das proteínas. A 125I-EPO revelou ser radioquimicamente estável durante 20 dias 
após a síntese. Um estudo biológico in vitro em linhas celulares tumorais demonstrou que a 125I-EPO 
apresenta uma ligação muito fraca (<2%), tanto em células normais como nas linhagens tumorais testadas. 
A biodistribuição em camundongos saudáveis apresentou taxas de fixação relativamente maiores nos 
órgãos excretores e a tireóide revelou ser o órgão crítico, o que pode indicar a dissociação in vivo da 
125I-EPO. No estudo em camundongos com melanoma induzido a fixação no tumor foi residual. Serão, 
no entanto, necessários novos estudos em outras linhagens tumorais para entender o seu processo de 
internalização e ligação nas células. Estudos da EPO radiomarcada com carbono-11 poderão também 
revelar-se interessantes, já que neste método há maior probabilidade da atividade biológica ser preservada.
Unitermos: Eritropoetina. Hormônio glicoprotéico. 125I-erythropoietin/síntese. 125I-erythropoietin/
avaliação biológica. Eritropoese/regulação. Iodo-125/marcador. Tumores expressores de EPO.
INTRODUCTION
Due to the increasing incidence of neoplastic di-
seases in contemporary society, concerted efforts are 
being made in oncologic research, both in the area of 
therapy and diagnosis. The existing methods of therapy 
are most effective when the disease is detected early. For 
this reason, efforts are being made to develop diagnostic 
techniques that are increasingly sensitive and specific in 
order to detect any abnormal cell proliferation as early as 
possible. Nuclear Medicine has made a significant contri-
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bution toward this goal because it allows the detection of 
malignant proliferations on a molecular scale before the 
manifestation of physiological symptoms or detection 
by other conventional imaging techniques. To this end, 
the use of erythropoietin (EPO) is currently the focus of 
metabolically oriented studies aimed at the detection of 
tumours.
EPO is a glycoprotein hormone that regulates 
erythropoiesis. It acts in the advanced stages of the 
erythrocyte progenitor cells by promoting proliferation, 
maturation and apoptosis inhibition in order to decrease 
cell death rate in bone marrow (Fisher, 2003). The main 
production site of this hormone is located in the kidney, 
although it is also produced in smaller quantities in the 
liver in response to low oxygen concentration levels in 
the blood. Hypoxia is a key concept in the production of 
EPO. Several studies have shown a relationship between 
some cancers and the stimulation of EPO production due 
to hypoxia (Acs et al., 2004a,b).
Many types of tumoral cells have a system of EPO 
autocrine production, which allows them to survive and 
proliferate under conditions of hypoxia (Lappin, 2003; 
Winter et al., 2005). Thus, EPO is strongly involved in 
growth, viability and angiogenesis of a large number of 
tumours (Eccles et al., 2003; Kumar et al., 2005; Yasuda, 
Fujita, Matsuo, 2003). This means that these tumoral cells 
have EPO receptors (EPOr) on their surfaces that can be 
used as targets for the early detection of cancers by using 
EPO labeled with a radionuclide.
Use of immunohistochemical methods has yielded 
evidence proving that EPOr are present in breast cancer 
cells but absent in adjacent tissues (Acs et al., 2002). This 
phenomenon seems to be a promising focus for future 
research directing chemotherapy agents to the EPOr of a 
tumour while sparing surrounding tissues (Lappin, 2003). 
This can also be important in Nuclear Medicine diagnosis 
or therapy through the labeling of EPO with iodine radio-
active isotopes (131I or 123I) that are easily introduced into 
tyrosine, histidine and histamine residues in proteins.
EPO has a molecular weight of around 30kD, is 
composed of 165 amino acids, four carbohydrate groups 
(some with sialic acid termination) while one of its most 
important structural aspects is the fact that it has two di-
sulfide bridges. One of these bridges ensures correct mo-
lecular form allowing binding to receptors. The breaking 
of this bridge leads to a loss of biological activity of the 
protein. Consequently, the introduction of an iodine atom 
in EPO is effected directly by electrophilic substitution, 
activated by electron-donor atoms (-OH, -NH2), with the 
various carbohydrate groups containing sialic acid. Thus, 
radioiodination by electrophilic substitution using lactope-
roxidase is the most appropriate method since it not only 
leads to higher specific activity, but is also a less aggressive 
method with a greater tendency to maintain the biological 
integrity of proteins (Murphy, 1976; Signore et al., 1992).
MATERIAL AND METHODS
In this study, the oxidative radioiodination of EPO 
was performed enzymatically by the lactoperoxidase 
method given this is a less aggressive method of protein 
radiolabeling.
EPO solution was prepared in phosphate buffered 
saline (PBS) with pH 7.4 (0.16 g/L). A volume of 25 μL 
of this solution was mixed with 15 MBq of Na125I, 4 μg of 
lactoperoxidase solution and 10 μL of H2O2 30%. The re-
action mixture was stirred in a vortex and radioiodination 
took place at room temperature.
To optimize reaction time, five EPO radioiodinations 
were carried out under the same conditions. Each was in-
terrupted by adding 150μl of sodium thiosulfate 10% after 
2, 5, 10, 20 and 30 minutes, respectively. Radiolabeling 
efficiency was calculated using an optimized TLC-SG 
chromatographic method with ethanol, ether and water 
(5:5:2) where 125I-EPO has an Rf of 0.0 and 
125I an Rf of 0.9.
The remaining free 125I was separated from radioio-
dinated EPO by gel permeation chromatography (Sepha-
dex G-25) with PBS at pH 7.4 as the eluent. The radioacti-
vity of each fraction was measured using a gamma counter. 
The 125I-EPO purified solution was kept at 6 ºC and an in 
vitro stability study was conducted for a 20-day period.
To analyze the binding rate of 125I-EPO to normal and 
neoplastic cells, V79 (Chinese Hamster Lung Fibroblast 
Cell Line) and B16-F1 (epithelial cells of mice melano-
ma) cell lines were used, respectively. These lines were 
incubated for 3 hours in a medium containing 125I-EPO 
(0.2 MBq/0.5 mL). For binding affinity control 0.5 mL of 
several modulator drugs were used: amiloride (1.3 mg/mL), 
chloroquine (2.6 mg/mL), quinacrine (2.3 mg/mL) and ou-
abain (3.6 mg/mL). Amiloride, chloroquine and quinacrine 
act as acidification inhibitors. Amiloride is also an inhibitor 
of Na+/H+ and Na+/K+ exchangers (Weiss, Lang, Bernhardt, 
2004) while quinacrine acts on cationic channels causing 
modification of kinetic parameters and other effects by 
binding to DNA and inhibiting NADH oxidoreductase in 
membrane. Ouabain is an inhibitor of Na+/K+ ATPase and 
modifies membrane permeability to ions (Lodish et al., 
2001). After three hours had elapsed, cells were analysed 
by optical microscopy. Cells were subsequently dissolved 
in 0.5 mL of NaOH 0.1 N with 1% sodium dodecyl sulfate, 
and centrifuged to separate them from unbound 125I-EPO. 
Finally, cells were controlled by a gamma counter.
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125I-EPO biodistribution was studied in mice in or-
der to characterize its in vivo behavior, more specifically 
its fixation in several tissues, including tumoral tissue. 
This study was conducted in two phases using female 
Balb/c strain mice. In the first phase, the labeled and pu-
rified compound, with a radiochemical purity of 100%, 
was injected intraperitoneally (approximately 0.6MBq) 
into 8 healthy animals that were sacrificed by dislocation 
of the neck at two different time intervals: four of these 
animals were sacrificed 1 hour after injection, and the 
remaining mice, 4 hours after injection. In the second 
phase, the experiment was repeated in three female mice 
with a melanoma induced by subcutaneous injection of 
B16-F1 tumour cells. All of the mice were sacrificed by 
dislocation of the neck 4 hours after 125I-EPO injection. 
Subsequently, the dissection of several organs of interest 
and neoplastic tissue was performed in order to measure 
their radioactivity using a dose calibrator. The biodistri-
bution results were analysed according to Tukey’s range 
test, with a value of p<0.05 considered significant. All 
the experiments were carried out in compliance with the 
guidelines for conduct in animal experimentation.
RESULTS AND DISCUSSION
Synthesis and stability of 125I-EPO
By varying the duration of the radioiodination 
reactions of EPO and evaluating their radiochemical 
purities, a time period that tends to be more favorable 
for this procedure was identified. Through this experi-
mentation it was concluded that the optimal labeling 
efficiency can be achieved after approximately 10 
minutes of reaction (Figure 1). Thus, all subsequent 
radioiodinations of EPO were based on a standardized 
10-minute reaction time which, associated with purifi-
cation by gel permeation chromatography (Sephadex 
G-25), consistently yielded final products with radio-
chemical purities exceeding 99%.
Results of the in vitro stability study confirmed 
that the 125I-EPO solution was stable for at least 20 days 
after radiolabeling and purification. On the sixth day 
after radioiodination, the compound exhibited a radio-
chemical purity of approximately 100%. At the end of 
the study, 125I-EPO had a radiochemical purity of around 
93%, thereby proving high stability in PBS at pH 7.4 
stored at 6 ºC.
In vitro study with tumoral cell lines
In vitro studies of the biological viability of 125I-
EPO showed negligible binding affinity (<2%) for all 
cell lines tested, although this was slightly higher in V79 
(Figure 2).
With regard to different modifiers used, two of 
these seemed to have a negative effect on cell binding 
affinity. Quinacrine, which led to lower binding rates, 
proved to be cytotoxic for both types of cell lines at the 
concentration used. This effect was visible under optical 
microscope. Amiloride appeared to have an inhibiting 
effect on the binding affinity of 125I-EPO in V79 cells, 
since it was the only modifier that presented higher 
binding percentages in B16-F1. Chloroquine showed a 
similar pattern to that seen in the control group, which 
may be indicative that this drug exerts no effect on the 
studied binding process. Finally, ouabain seemed to have 
a positive strengthening effect on V79 binding affinity.
Thus, this study demonstrates that 125I-EPO had a 
weak binding affinity in the normal (V79) and tumoral 
(B16-F1) cell lines studied. These results may indicate 
that none of the tested cells expressed EPOr or that there 
may be a possible loss of biological activity caused by 
the incorporation of iodine in the molecule.
FIGURE 1 – Radiochemical purity of 125I-EPO by radioiodination 
time.
FIGURE 2 – Mean binding affinity of 125I-EPO in V79 and 
B16-F1 cell lines.
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Biodistribution in animal model
After dissection of the mice, the injected dose (ID) 
per tissue (Eq. 1) and per gram of tissue (Eq. 2), were 
calculated for each animal.
 Eq. 1
 Eq. 2
The fixation of radioactivity verified in mice sacri-
ficed 4 hours after injection was shown to be lower than 
that in mice sacrificed after 1 hour (Figure 3A). This is 
because excretion increases with time after injection. The 
kidney and liver are the main routes of excretion and so 
have higher fixation rates. The levels of 125I-EPO in the 
blood are also high because of slow clearance of EPO 
(4h<T1/2<11h) (Kendall, 2001). The high radioactivity 
observed in thyroid, an organ that has a natural ability to 
capture iodine, suggests that, despite the observed in vitro 
stability, there may be some in vivo dissociation of 125I-
EPO, since the solution injected in the mice was almost 
completely free of iodine. The values obtained in the asses-
sment of the mice with induced melanoma demonstrated a 
residual fixation of 125I-EPO in tumour (Figure 3B) while 
other organs showed expected level of fixation, based on 
a previous study with a healthy animal model.
Owing to the suspected in vivo 125I-EPO dissociation, 
a TLC-SG chromatography of the urine collected from 
one of the mice sacrificed 4 hours after injection was per-
formed. Results revealed the presence of a radiochemical 
species with an Rf corresponding to iodine (Rf = 0.9). 
This further supported the theory of 125I-EPO deiodination 
inside the body.
CONCLUSIONS
In this study, EPO radiolabeling with 125I was perfor-
med to evaluate its potential as a diagnostic or therapeutic 
radiopharmaceutical in molecular imaging. This radioiso-
tope of iodine was chosen for having the most appropriate 
characteristics for research purposes (low gamma emis-
sion energy, 35 keV, and a long half-life of 60 days) and 
because it mimics the use of 131I or 123I for radiotherapy or 
diagnostic radiopharmaceuticals, respectively.
The relative ease of radioiodination and purification 
of the molecule, the reproducibility of the process and its 
high stability, demonstrated by radiochemical purity as 
around 93% after 20 days of synthesis, are parameters 
that render 125I-EPO a physicochemically desirable radio-
pharmaceutical for use in Nuclear Medicine laboratories.
The biological tests began with an in vitro study on 
normal and tumoral (V79 and B16-F1) cell lines, in an at-
tempt to examine the binding mechanism of radioiodinated 
EPO. This procedure revealed that 125I-EPO has a weak 
binding affinity to cells, since the binding values were very 
low (<2%). However, further studies on new cell lines are 
needed to confirm whether the weak binding affinity is due 
to the absence of specific receptors in the cells used or to 
the biological activity lost during EPO radioiodination.
Studying biodistribution in an animal model is an 
essential stage in the development of any radiopharma-
ceutical. The in vivo behavior of 125I-EPO was investigated 
by intraperitoneal injection into healthy mice and animals 
with induced melanoma. The peritoneal cavity was chosen 
because it offers a greater absorption surface allowing faster 
entry into the bloodstream without the losses associated with 
FIGURE 3 – Biodistribution of 125I-EPO in mice. A. Comparative 
study in healthy mice; B. Study in 4h sacrificed mice with 
induced melanoma.
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intravenous injection in the tail of the animals. The results in 
healthy mice showed an expected biodistribution pattern in 
which the organs involved in the excretion mechanism, such 
as liver and kidneys, had comparatively high fixation rates. 
Thyroid proved to be the critical organ, which may indicate 
the in vivo dissociation of 125I-EPO. In the study involving 
mice with melanoma, induced by subcutaneous injection of 
B16-F1 tumour cells, the uptake of the radiation in neoplastic 
tissue was residual. This result should be expected since this 
same cell line showed very low levels of binding affinity in 
the in vitro study. Further biodistribution analysis in animals 
with different tumours, such as breast cancer, is now warran-
ted. This is the best means of ascertaining whether the poor 
binding affinity to tumours stems from complete in vivo deio-
dination, from loss of biological activity of the radioiodinated 
EPO, or if the tumoral cell line used is not a good example of 
an EPOr expressor tumour.
In any event, it seems to be worthwhile to continue 
our efforts toward developing a new radiopharmaceutical 
based on EPO. This research work was intended as a first 
step toward providing new perspectives for the develo-
pment of this radiotracer. Numerous future studies will 
be needed to better understand the biological activity of 
EPO and its process of binding and internalization in the 
cells of a range of tumours. Acquisition of scintigraphic 
images of animals injected with 123I-EPO may also be of 
great importance in evaluating the true capacity of this 
potential diagnostic radiopharmaceutical.
Given the advances in recent years in the field of mo-
lecular imaging, it might also be useful to conduct a study of 
11C-labeled EPO as a potential positron emitter radiophar-
maceutical. In this case the radioisotope would be a carbon 
atom, a natural element to the molecule, whose biological 
activity would remain unchanged after radiolabeling.
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